SCARLETRED Inc. Company Profile

Background

Overview

SCARLETRED Inc. is a leading health technology company specializing in standardized skin imaging and AI-powered objective skin analysis. Founded in 2014, the company is headquartered in Cambridge, Massachusetts, USA, with additional offices in Vienna, Austria. SCARLETRED's mission is to design, develop, and deliver certified Software as a Medical Device (SaMD) products and cutting-edge AI-driven data analysis services that transform how skin conditions are documented, assessed, and monitored. The company's vision is to enable healthcare professionals and patients to standardize skin imaging, objectify disease and treatment evaluation, and accelerate data collection and analysis in clinical trials and routine care worldwide.

Industry Significance

SCARLETRED holds a significant position in the dermatology and telemedicine sectors by addressing the challenges of subjective skin assessments and the lack of standardization in skin imaging. Its innovative solutions have been recognized globally, with the company being featured by ADVANTAGE AUSTRIA USA as a digital dermatology pioneer.

Key Strategic Focus

Core Objectives

SCARLETRED aims to revolutionize dermatology by providing standardized, reproducible, and regulator-ready skin data across more than 3,000 skin diseases and a wide range of safety-related applications. The company's solutions are designed to enhance the precision, traceability, and standardization required for modern dermatology and state-of-the-art clinical research.

Areas of Specialization

The company specializes in:

• Standardized Skin Imaging: Utilizing mobile 2D/3D and dermoscopic imaging to capture consistent and reproducible skin images.

• AI-Powered Skin Analysis: Employing artificial intelligence to objectively assess skin conditions, including lesion size, geometry, depth, color parameters, and surface characteristics.

• Clinical Trial Support: Providing electronic Clinical Outcome Assessment (eCOA) tools to enhance data collection and analysis in clinical trials.

Key Technologies Utilized

SCARLETRED leverages several advanced technologies:

• Mobile Imaging Platforms: Developing mobile applications compatible with iOS and Android devices to facilitate widespread adoption.

• AI and Machine Learning: Integrating AI algorithms to analyze skin images and detect various dermatological features.

• Cloud-Based Data Management: Utilizing secure cloud platforms for data storage, processing, and analysis, ensuring scalability and accessibility.

Primary Markets Targeted

SCARLETRED's solutions cater to:

• Biopharmaceutical Companies: Enhancing drug development processes through precise skin assessments.

• Cosmetics Industry: Validating product efficacy and safety with objective skin analysis.

• Healthcare Providers: Improving patient care with standardized skin imaging and monitoring tools.

• Clinical Research Organizations: Streamlining data collection and analysis in dermatological studies.

Financials and Funding

Funding History

SCARLETRED has secured multiple funding rounds to support its growth and innovation:

• June 2020: Received non-equity assistance from EIT Health.

• April 2020: Awarded a grant from The Austrian Research Promotion Agency (FFG).

• January 2020: Secured a grant from Vienna Business Agency.

• September 2019: Obtained a grant from austria Wirtschaftsservice (aws).

• October 2018: Completed an equity crowdfunding round through Green Rocket GmbH.

• November 2017: Received non-equity assistance from Die Wirtschaftskammer.

• October 2017: Awarded a grant.

• February 2017: Secured a grant.

• July 2016: Completed a seed round with austria Wirtschaftsservice (aws).

• January 2016: Received private equity funding from founder Harald Schnidar.

Total Funds Raised

The company has raised a total of approximately $2.1 million across various funding rounds.

Notable Investors

Key investors include:

• EIT Health: A European network of best-in-class health innovators.

• The Austrian Research Promotion Agency (FFG): Austria's national funding agency for industrial research and development.

• Vienna Business Agency: Supports Vienna-based companies in their growth and internationalization efforts.

• Green Rocket GmbH: A crowdfunding platform focusing on sustainable and innovative projects.

• Die Wirtschaftskammer: The Austrian Federal Economic Chamber, representing the interests of Austrian businesses.

• austria Wirtschaftsservice (aws): Austria's federal promotional bank supporting businesses and startups.

Utilization of Capital

The raised capital has been utilized for:

• Product Development: Enhancing the Scarletred® Vision platform and expanding its capabilities.

• Regulatory Compliance: Ensuring products meet international standards and certifications.

• Market Expansion: Entering new markets and establishing a global presence.

• Operational Scaling: Building infrastructure to support growing customer demands.

Pipeline Development

Key Pipeline Candidates

SCARLETRED's primary product is the Scarletred® Vision system, a certified medical device that provides standardized skin imaging and AI-powered analysis. The company is also developing the Superoxide Dismutase biologic, focusing on chronic skin wounds and protection against severe skin damage.

Stages of Development

• Scarletred® Vision: Marketed and in use since 2015, with continuous updates and enhancements.

• Superoxide Dismutase Biologic: Under clinical development for various dermatological applications.

Target Conditions

• Scarletred® Vision: Applicable across more than 3,000 skin diseases and safety-related applications.

• Superoxide Dismutase Biologic: Targeting chronic skin wounds and severe skin damage from irradiation or thermal energy.

Anticipated Milestones

• Scarletred® Vision: Ongoing product enhancements and market expansion.

• Superoxide Dismutase Biologic: Advancing through clinical trial phases with expected regulatory submissions in the near future.

Technological Platform and Innovation

Proprietary Technologies

• Scarletred® Vision: A mobile medical device software that enables standardized skin imaging and analysis.

• Superoxide Dismutase Biologic: A recombinant human SOD biologic under development for dermatological applications.

Significant Scientific Methods

• AI-Powered Analysis: Utilizing machine learning algorithms to assess skin images objectively.

• Mobile Imaging: Employing smartphone-based imaging to facilitate widespread adoption and ease of use.

AI-Driven Capabilities

• ARORA®: An AI agent integrated into the Scarletred® Vision system that automates assessment of skin types and ensures privacy compliance by blinding personally identifiable information.

Leadership Team

Executive Profiles

• Harald Schnidar, PhD MBA: Founder, CEO, and President. Dr. Schnidar has a background in medical technology and business administration, leading SCARLETRED since its inception.

• Kathrin Schnidar, BSc: Chief Financial Officer. Ms. Schnidar oversees financial operations and strategic financial planning for the company.

• Stefan Schnidar, MSc: Chief Technology Officer. Mr. Schnidar is responsible for the technological direction and development of SCARLETRED's products.

Advisory Board Members

• Dr. Richard Partl: Specializes in oncology and clinical R&D.

• Dr. Christian Posch: Board-certified dermatologist with expertise in skin diseases.

• Dr. Hannes Trattner: Board-certified dermatologist focusing on dermatological treatments.

• Alexander Habinski: SaaS expert with experience in software as a service solutions.

Competitor Profile

Market Insights and Dynamics

The dermatology market is marked by increasing demand for objective and standardized skin assessment technologies. Competitors in this sector focus on leveraging AI, telemedicine, and advanced imaging but often lack integrated, certified medical device solutions that comply with regulatory standards to the extent SCARLETRED offers. This creates a competitive landscape where differentiation depends largely on technological innovation, regulatory compliance, and the ability to scale clinical evidence across diverse indications.

Competitive Positioning

SCARLETRED distinguishes itself through:

• Regulatory certification of its Scarletred® Vision system as a Software as a Medical Device (SaMD).

• Comprehensive AI-driven image processing combined with standardized imaging protocols.

• A versatile solution applicable to clinical trials, biopharma drug development, cosmetics efficacy evaluation, and routine clinical care.

Competitors tend to focus singularly on either imaging hardware, standalone AI algorithms, or data management platforms without fully integrating these components into a regulatory-grade system.

Competitive Technologies

Other players employ various imaging modalities, including smartphone applications, dermoscopy, and multispectral imaging, alongside AI for lesion detection and classification. However, many competitors lack certified device status or the depth of clinical trial integration that SCARLETRED provides.

Market Challenges

Competitors face challenges in gaining regulatory approval and demonstrating clinical validity to an extent required by pharmaceutical sponsors and healthcare providers. Additionally, scalability and data privacy compliance represent ongoing hurdles that SCARLETRED addresses with its cloud-based, AI-automated, and privacy-conformant platform.

Strategic Initiatives

Some competitors are exploring partnerships and merging AI capabilities with teledermatology platforms to enhance reach. SCARLETRED’s pathway includes ongoing product innovation, pipeline expansion into biologics for skin repair, and strategic collaborations with biopharma and clinical research organizations to maintain leadership.